摘要
探讨明胶－阿霉素抗癌缓释剂治疗膀胱肿瘤的临床可行性。方法应用含２０％小牛血清的完全培养基浸泡明胶－阿霉素抗癌缓释剂，将不同时间所得的培养基分别行阿霉素药物浓度测定及与膀胱肿瘤细胞株ＢＩＵ－８７混合培养。结果明胶－阿霉素抗癌缓释剂可于体外释放２１天，第１至第１９天释出药物对ＢＩＵ－８７细胞具有生长抑制作用，其释出药物浓度与ＢＩＵ－８７细胞生长率呈明显负相关（ｒ＝－０．６７１８，Ｐ＜０．０１）。结论明胶－阿霉素抗癌缓释剂应用于临床治疗膀胱肿瘤具有可行性。
Objective To investigate the possibility of the gelatia-adriamycin antineoplastic sustained release drug system (ASRDS) in the treatment of bladder tumors. Method Gelatia-adrlamycinASRDS was impregnated into the culture-medium containing 20% bovine serum, and the medium wassubstituted every 24 h. Then the human bladder tumor cell line BIU-87 as incubated with the mediumsubstituted every day. The level of adriamycin in medium was measured at the same time. Result TheASRDS could release for 21 days in vitro, had growth suppression effects on the BIU-87 cell line from1st to 19th day. The growth rate of BIU-87 cells was negatively related to the level of adriamycin in themedium substituted every day (r=-0. 6718, P<0. 01). Conclusion Gelatia-adriamycin ASRDS couldbe used in the treatment of bladder tumors.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
1999年第2期177-178,共2页
Chinese Journal of Experimental Surgery
基金
国家教委!教外国留[1995]806号
